These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31646624)

  • 1. HLA-B*51:01 and CYP2C9*3 Are Risk Factors for Phenytoin-Induced Eruption in the Japanese Population: Analysis of Data From the Biobank Japan Project.
    Hikino K; Ozeki T; Koido M; Terao C; Kamatani Y; Mizukawa Y; Shiohara T; Tohyama M; Azukizawa H; Aihara M; Nihara H; Morita E; Murakami Y; Kubo M; Mushiroda T
    Clin Pharmacol Ther; 2020 May; 107(5):1170-1178. PubMed ID: 31646624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA Alleles and CYP2C9*3 as Predictors of Phenytoin Hypersensitivity in East Asians.
    Su SC; Chen CB; Chang WC; Wang CW; Fan WL; Lu LY; Nakamura R; Saito Y; Ueta M; Kinoshita S; Sukasem C; Yampayon K; Kijsanayotin P; Nakkam N; Saksit N; Tassaneeyakul W; Aihara M; Lin YJ; Chang CJ; Wu T; Hung SI; Chung WH
    Clin Pharmacol Ther; 2019 Feb; 105(2):476-485. PubMed ID: 30270535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin-Induced Cutaneous Adverse Drug Reactions.
    Fohner AE; Rettie AE; Thai KK; Ranatunga DK; Lawson BL; Liu VX; Schaefer CA
    Clin Transl Sci; 2020 Sep; 13(5):1004-1009. PubMed ID: 32216088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions.
    Yampayon K; Sukasem C; Limwongse C; Chinvarun Y; Tempark T; Rerkpattanapipat T; Kijsanayotin P
    Eur J Clin Pharmacol; 2017 Jul; 73(7):855-865. PubMed ID: 28391407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population.
    Tassaneeyakul W; Prabmeechai N; Sukasem C; Kongpan T; Konyoung P; Chumworathayi P; Tiamkao S; Khunarkornsiri U; Kulkantrakorn K; Saksit N; Nakkam N; Satapornpong P; Vannaprasaht S; Sangviroon A; Mahasirimongkol S; Wichukchinda N; Rerkpattanapipat T; Tassaneeyakul W
    Pharmacogenet Genomics; 2016 May; 26(5):225-34. PubMed ID: 26928377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children.
    Suvichapanich S; Jittikoon J; Wichukchinda N; Kamchaisatian W; Visudtibhan A; Benjapopitak S; Nakornchai S; Manuyakorn W; Mahasirimongkol S
    J Hum Genet; 2015 Aug; 60(8):413-7. PubMed ID: 25994870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes.
    Yamamoto Y; Takahashi Y; Imai K; Miyakawa K; Ikeda H; Ueda Y; Yamaguchi T; Nasu H; Ohtani H; Shigematsu H; Kagawa Y; Inoue Y
    Ther Drug Monit; 2015 Apr; 37(2):229-35. PubMed ID: 25162219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.
    Chung WH; Chang WC; Lee YS; Wu YY; Yang CH; Ho HC; Chen MJ; Lin JY; Hui RC; Ho JC; Wu WM; Chen TJ; Wu T; Wu YR; Hsih MS; Tu PH; Chang CN; Hsu CN; Wu TL; Choon SE; Hsu CK; Chen DY; Liu CS; Lin CY; Kaniwa N; Saito Y; Takahashi Y; Nakamura R; Azukizawa H; Shi Y; Wang TH; Chuang SS; Tsai SF; Chang CJ; Chang YS; Hung SI; ;
    JAMA; 2014 Aug; 312(5):525-34. PubMed ID: 25096692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients.
    Thakkar AN; Bendkhale SR; Taur SR; Gogtay NJ; Thatte UM
    Neurol India; 2012; 60(6):577-80. PubMed ID: 23287317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
    Chang WC; Hung SI; Carleton BC; Chung WH
    Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):723-734. PubMed ID: 32510242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese.
    Cheung YK; Cheng SH; Chan EJ; Lo SV; Ng MH; Kwan P
    Epilepsia; 2013 Jul; 54(7):1307-14. PubMed ID: 23692434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese.
    Man CB; Kwan P; Baum L; Yu E; Lau KM; Cheng AS; Ng MH
    Epilepsia; 2007 May; 48(5):1015-8. PubMed ID: 17509004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between CYP2C9/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: A systematic review and meta-analysis
.
    Liao K; Liu Y; Ai CZ; Yu X; Li W
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):337-346. PubMed ID: 29628024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.
    Caudle KE; Rettie AE; Whirl-Carrillo M; Smith LH; Mintzer S; Lee MT; Klein TE; Callaghan JT;
    Clin Pharmacol Ther; 2014 Nov; 96(5):542-8. PubMed ID: 25099164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating the association of Lamotrigine and Phenytoin-induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis with HLA-B*1502 in Iranian population.
    Sabourirad S; Mortezaee R; Mojarad M; Eslahi A; Shahrokhi Y; Kiafar B; Jarahi L; Afkhami Ardakani S; Farrokhi S
    Exp Dermatol; 2021 Feb; 30(2):284-287. PubMed ID: 33217035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance.
    Kousar S; Wafai ZA; Wani MA; Jan TR; Andrabi KI
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):504-16. PubMed ID: 25943175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population.
    Hu FY; Wu XT; An DM; Yan B; Stefan H; Zhou D
    Seizure; 2011 Mar; 20(2):160-2. PubMed ID: 21169036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of CYP2C9*3 with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis.
    Wu X; Liu W; Zhou W
    J Clin Pharm Ther; 2018 Jun; 43(3):408-413. PubMed ID: 29274302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of cutaneous adverse reactions to aromatic antiepileptic drugs and human leukocyte antigen genotypes in Thai patients and meta-analysis.
    Sukasem C; Sririttha S; Chaichan C; Nakkrut T; Satapornpong P; Jaruthamsophon K; Jantararoungtong T; Koomdee N; Medhasi S; Oo-Puthinan S; Rerkpattanapipat T; Klaewsongkram J; Rerknimitr P; Tuchinda P; Chularojanamontri L; Tovanabutra N; Suvannang N; Rungrotmongkol T; Saokaew S; Aekplakorn W; Puangpetch A
    Pharmacogenomics J; 2021 Dec; 21(6):682-690. PubMed ID: 34175889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study.
    Sato T; Cheng CL; Park HW; Kao Yang YH; Yang MS; Fujita M; Kumagai Y; Tohkin M; Saito Y; Sai K
    Clin Transl Sci; 2021 May; 14(3):1002-1014. PubMed ID: 33382928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.